Phase II study of mitomycin C, etoposide and vindesine in metastatic stage IV non-small-cell lung cancer.
A total of 72 patients with metastatic stage IV non-small-cell lung cancer (NSCLC) were treated with combination chemotherapy comprising the MEV regimen (mitomycin C, 8 mg/m2 given i.v. on day 1; etoposide, 100 mg/m2 given i.v. on days 1-3; and vindesine, 3 mg/m2 given i.v. on day 1; treatment repeated every 3 weeks). In 65 evaluable patients, the objective response rate was 37% (complete responses, 4.7%; partial responses, 32.3%). The median survival was 7.6 months for all patients. The treatment was very well tolerated. MEV proved to be an active and non-toxic regimen for the treatment of metastatic NSCLC.
Gridelli
C
C
Cattedra di Oncologia Medica, II Facoltà di Medicina, Università di Napoli, Italia.
Pepe
R
R
Palmeri
S
S
Iacobelli
S
S
Gentile
M
M
Gebbia
V
V
Garufi
C
C
Airoma
G
G
Palmieri
G
G
Russo
A
A
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D004341:Drug Evaluation; D005047:Etoposide / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D008207:Lymphatic Metastasis; D016685:Mitomycin / Q000008:administration & dosage / Q000009:adverse effects; D009367:Neoplasm Staging; D012074:Remission Induction; D013997:Time Factors; D014751:Vindesine / Q000008:administration & dosage / Q000009:adverse effects
D016685:Mitomycin; D005047:Etoposide; D014751:Vindesine